PubRank

Maria Alma Rodriguez

Author PubWeight™ 20.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010 2.82
2 Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 2013 2.01
3 Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010 1.85
4 Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood 2013 1.60
5 A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003 1.49
6 Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 2014 1.43
7 Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009 1.16
8 Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol 2008 1.15
9 Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 2004 1.05
10 The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 2014 0.91
11 The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk 2012 0.88
12 Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer 2014 0.82
13 Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol 2013 0.82
14 Difficult discharge: lessons from the oncology setting. Am J Bioeth 2007 0.82
15 Misdiagnosis: Disclosing a Colleague's Error. J Oncol Pract 2008 0.80
16 Can physicians refuse treatment to patients who smoke? J Oncol Pract 2009 0.79
17 Medical errors: physician and institutional responsibilities. J Oncol Pract 2009 0.79
18 A multidisciplinary team approach to improving psychosocial care in patients with cancer. Clin J Oncol Nurs 2013 0.76